Investors
|
Careers
|
Contact Us
Company Overview
Company Overview
Management Team
Board of Directors
Scientific Advisory Board
Collaborations
Business Development
:
Product Pipeline
Product Pipeline
Proprietary Programs
Betrixaban
PRT064445: FXa Inhibitor Antidote
PRT062607: Syk-Specific Inhibitor
PRT062070: Dual Syk-JAK Inhibitor
JAK3 Program
Partnered Programs
Elinogrel
Clinical Trials
Publications
:
Therapeutic Areas
Therapeutic Areas
Thrombosis Overview
Anticoagulant Market
Rheumatoid Arthritis and Systemic Lupus Erythematosus Overview
Antiplatelet Market
:
Newsroom
Newsroom
News Releases
Portola in the News
Publications
Site Map
Site Map
Company Overview
Management Team
Board of Directors
Scientific Advisory Board
Collaborations
Business Development
Investors
Careers
Contact Us
Portola Profiles
Terms of Use
Privacy Policy
Product Pipeline
Thrombosis Programs
Elinogrel
Betrixaban
PRT064445: FXa Inhibitor Antidote
Inflammation Programs
PRT062607: Syk-Specific Inhibitor
PRT062070: Dual Syk-JAK Inhibitor
JAK3 Program
Clinical Trials
Publications
Therapeutic Areas
Thrombosis Overview
Antiplatelet and Anticoagulant Markets
Rheumatoid Arthritis Overview
Newsroom
News Releases
Portola in the News
Publications
